BioAtla, Inc.(BCAB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 42 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BCAB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for BioAtla, Inc. (BCAB), a Healthcare sector company. BCAB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 42 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q4 2025), BioAtla, Inc. reports net income of $-9.8M, free cash flow of $-7.9M. Top institutional holders of BCAB by reported 13-F value include ACORN CAPITAL ADVISORS,, MILLENNIUM MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BCAB trades on the Nasdaq exchange and files with the SEC under CIK 1826892. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioAtla, Inc. directly from SEC EDGAR. BioAtla, Inc.'s 13F Pro composite quality score has ranged between 23 and 28 since 2022, currently 23.4 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.
Net Income
Q4 2025
$-9.8M
Free Cash Flow
Q4 2025
$-7.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+14.6% YoYOperating Income
+19.8% YoYEPS (Diluted)
+29.9% YoYTotal Assets
-73.6% YoYOp. Cash Flow
+33.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $300.0K | — |
| Net Income | $-59.6M +14.6% | $-69.8M +43.5% | $-123.5M -15.9% | $-106.5M -11.6% | $-95.4M -166.1% | $-35.9M |
| Operating Income | $-59.3M +19.8% | $-73.9M +43.0% | $-129.7M -19.9% | $-108.1M -12.1% | $-96.4M -220.4% | $-30.1M |
| EPS (Diluted) | $-1.01 +29.9% | $-1.44 +44.2% | $-2.58 +5.8% | $-2.74 +0.7% | $-2.76 | — |
| Total Assets | $13.8M -73.6% | $52.4M -56.2% | $119.7M -47.0% | $225.7M -11.3% | $254.4M +3.9% | $244.9M |
| Operating Cash Flow | $-48.2M +33.0% | $-71.9M +30.8% | $-104.0M -15.0% | $-90.4M -45.3% | $-62.2M -71.2% | $-36.3M |
Get alerted when BCAB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BioAtla, Inc. including:
Top Institutional Holders of BCAB
ACORN CAPITAL ADVISORS, LLC
$865.0K5,406,345 shMILLENNIUM MANAGEMENT LLC
$443.8K2,756,674 shVANGUARD CAPITAL MANAGEMENT LLC
$265.5K1,649,252 shGEODE CAPITAL MANAGEMENT, LLC
$111.0K689,182 shDEUTSCHE BANK AG\
$84.1K525,352 shRENAISSANCE TECHNOLOGIES LLC
$82.2K510,514 shBlackRock, Inc.
$77.4K480,931 shCITADEL ADVISORS LLC
$70.1K435,675 shUBS Group AG
$60.5K375,569 shMARSHALL WACE, LLP
$44.4K277,630 sh
| Fund | Value | Shares |
|---|---|---|
| ACORN CAPITAL ADVISORS, LLC | $865.0K | 5,406,345 |
| MILLENNIUM MANAGEMENT LLC | $443.8K | 2,756,674 |
| VANGUARD CAPITAL MANAGEMENT LLC | $265.5K | 1,649,252 |
| GEODE CAPITAL MANAGEMENT, LLC | $111.0K | 689,182 |
| DEUTSCHE BANK AG\ | $84.1K | 525,352 |
| RENAISSANCE TECHNOLOGIES LLC | $82.2K | 510,514 |
| BlackRock, Inc. | $77.4K | 480,931 |
| CITADEL ADVISORS LLC | $70.1K | 435,675 |
| UBS Group AG | $60.5K | 375,569 |
| MARSHALL WACE, LLP | $44.4K | 277,630 |
More Healthcare Companies
View all Healthcare →Put BCAB on your watchlist
Track score changes the day BioAtla, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BCAB a good stock to buy?
13F Pro's AI-powered analysis of BioAtla, Inc. (BCAB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BCAB are available on the BCAB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BCAB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BCAB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BioAtla, Inc.'s investment landscape.